

**ASX Release Stock Code: PRR / Media Release**

**Friday 6<sup>th</sup> March 2009**

**PRIMA BIOMED COMMENCES CVac™ CANCER THERAPY PATIENT  
TREATMENT**

Australian cancer treatment development company Prima BioMed (ASX: PRR) is pleased to announce that it has commenced patient treatment of the Company's CVac™ ovarian cancer treatment.

The patient will receive the CVac™ treatment today via the Australian Regulatory Control Mechanism's Special Access Scheme under the TGA.

Prima BioMed is making rapid progress towards the commercialisation of CVac™ into the multi-billion global ovarian cancer therapy market, including a successful pre-Investigational New Drug Application (preIND) meeting with the US Food and Drug Administration (FDA) late last year – a key step in the pathway to commercialisation of new drug applications.

The current patient treatment represents another important step in the commercialisation process.

The injection of the CVac™ vaccine in ovarian cancer patients works as a post-surgery and post-chemotherapy maintenance therapy to delay relapse and control metastases. Ovarian cancer has a very high morbidity rate and there is a massive un-met global market. Currently there are no ovarian cancer maintenance therapy products available.

The Company looks forward to updating the market on the progress of its patient treatments, and also on its continued progress to commercialisation of CVac™, in the near future.

**For further information please contact:**

Mr Martin Rogers  
Director  
Prima BioMed  
Ph: 02 9232 4420  
E: martin.rogers@primabiomed.com.au

James Moses  
Investor and Media Relations  
Mandate Corporate  
Ph: 0420 991 574  
E: james@mandatecorporate.com.au

Website: [www.primabiomed.com.au](http://www.primabiomed.com.au)



### **About CVac™ Ovarian Cancer Treatment**

CVac™ is Prima Biomed's lead product. It is of key importance as there is a large unmet medical need for new treatments for ovarian cancer which has a very high morbidity rate. CVac™ is a maintenance therapy administered post-surgery and post-chemotherapy to delay relapse and control metastases.

There are currently no products available as maintenance based therapies for ovarian cancer and the global market for ovarian cancer therapeutics was valued at US\$2.1b in 2007 and is expected to total US\$3.6b by 2010.

Regulatory approval of CVac™ over the next 6-9 months is the core focus for Prima.

### **About Prima BioMed**

Prima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology. Prima's lead product is the CVac™ ovarian cancer therapy treatment. It has completed two successful clinical trials and is in the final stages of US FDA approval and eventual commercialisation.

The Company's broader, long term goal is develop commercial cancer treatment technologies and programs for global markets.